You searched for "Renal"
Prostate biopsies without antibiotic cover – are we there yet?
Transperineal (TP) prostate biopsies are widely replacing the traditional transrectal route due to definite evidence of reduced infective complications. TP biopsies are usually performed with a single dose of antibiotic pre-procedure in most centres. In this article the authors attempt...MAPLe – the pelvic floor in high definition. One probe, all dysfunctions
The MAPLe high-definition technology enables you to diagnose and view a patient’s individual pelvic floor muscle EMG activity at a glance, making it possible for you to provide a more...The Re-humanising Revolution: Breaking the conspiracy of silence
Over the last few years, the mental and emotional wellbeing of those who work in medicine has come under scrutiny. The author introduces a new resource. Working in healthcare has always been stressful but never more so than today. In...In conversation with James Green
We were delighted to catch up with James Green, Consultant Urological Surgeon and new President of the Royal Society of Medicine Section of Urology. Can you tell us a little bit about what led you into the field of urology...How an ergonomic design is helping women overcome barriers in ISC
Urinary incontinence, or loss of bladder control, is a frustrating problem for millions of people. Never knowing when and where one might have an accident can affect everything: from work to family and social life. It happens to both men...Training to be a urologist: how risky is it?
The NHS and urology face challenging times in trying to provide quality patient care efficiently and economically. Urology trainees are experiencing conflicting pressures with a new contract, a challenging on-call system and changing training requirements in an overstretched, centralised service...
Activity of enzalutamide in men with mCRPC is affected by prior treatment with abiraterone and / or docetaxel
This study reported on the real-world clinical outcomes of patients at seven academic institutions who were treated with enzalutamide, with the primary objective being to assess the effect of prior therapies (namely abireterone and docetaxel). Three hundred and ten patients...
The EP2 receptor – a novel target for prostate cancer?
This basic science paper sets out to evaluate the effects that celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, have on prostate cancer cell lines and evaluated the mechanisms behind these effects. COX-2 induces the production of prostaglandins, which promote cell proliferation...
